Source comparison
BPC-157 Wound Healing Protocol Dosage Timing Comparison
| Protocol Type | Dosage | Frequency | Timing Window | Injection Site | Best Use Case | Professional Assessment ||—|—|—|—|—|—|| Acute Injury (First 48 Hours) | 250mcg | Twice daily (12-hour spacing) | Within 24 hours of injury | Within 2–4 inches of injury | T
This comparison does not assign a generated winner or score.
- | Protocol Type | Dosage | Frequency | Timing Window | Injection Site | Best Use Case | Professional Assessment ||—|—|—|—|—|—|| Acute Injury (First 48 Hours) | 250mcg | Twice daily (12-hour spacing) | Within 24 hours of injury | Within 2–4 inches of injury | Tendon strains, ligament sprains, muscle tears | Optimal. Captures inflammatory phase when growth factor receptors peak || Delayed Acute (72 Hours – 7 Days) | 250–350mcg | Twice daily | 3–7 days post-injury | Near injury site | Injuries where immediate treatment wasn't possible | Effective but reduced magnitude. Proliferative phase already underway || Chronic Tendinopathy | 250–300mcg | Once daily | Ongoing (4–8 week cycles) | Rotation of sites near affected tissue | Persistent tendon pain, repetitive strain | Lower dose acceptable. Not targeting acute inflammation || Gastrointestinal Repair | 500mcg–1mg | Once daily (oral) | 30 minutes before first meal | Oral capsule | Gastric ulcers, IBD flare-ups, mucosal damage | Oral route pr